Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
نویسندگان
چکیده
BACKGROUND & AIMS Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results. Treatment with somatostatin analogues slowed kidney growth in patients with polycystic kidney disease (PKD) and reduced liver and kidney volume in a PKD rodent model. We evaluated the effects of lanreotide, a somatostatin analogue, in patients with polycystic liver because of autosomal-dominant (AD) PKD or autosomal-dominant polycystic liver disease (PCLD). METHODS We performed a randomized, double-blind, placebo-controlled trial in 2 tertiary referral centers. Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks. The primary end point was the difference in total liver volume, measured by computerized tomography at weeks 0 and 24. Analyses were performed on an intention-to-treat basis. RESULTS Baseline characteristics were comparable for both groups, except that more patients with ADPKD were assigned to the placebo group (P = .03). The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide. In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01). Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases). CONCLUSIONS In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
منابع مشابه
A PROSPECTIV E, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF DEXAMETHASONE DURING THE FOLLICULAR PHASE IN CLOMIPHENE RESISTANT PATIENTS WITH POLYCYSTIC OVARY SYNDROME AND NORMAL DHEAS
In order to evaluate the effects of short course administration of dexamethasone (DEX) combined with clomiphene citrate (CC) in CC-resistant patients with polycystic ovary syndrome (PCaS) and normal DHEAS, a prospective, double blind, placebo controlled, randomized study was undertaken at referral university hospitals, Two-hundred and thirty women with PCOS and normal DHEAS who failed to ...
متن کاملEffect of saffron on liver metastases in patients suffering from cancers with liver metastases: A randomized, double blind, placebo-controlled clinical trial
Objective: Cancer represents the second cause of mortality in the world. Saffron as a medicinal plant is known for its anti-cancer and anti-depressant properties. In this randomized double blind clinical trial, the effects of saffron on response to treatment in patients suffering from liver metastasis were evaluated. Materials and Methods: Thirteen patients suffering from liver metastases who r...
متن کاملThe efficacy of oral Erythromycin in the treatment of patients with Pityriasis Rosea: A randomized double-blind, placebo-controlled clinical trial
Background: Pityriasis rosea is an acute, inflammatory and self-limited disease, which is characterized by a primary scaly plaque (Herald patch) followed by a generalized, symmetrical papulosqumous eruption (Mostly on trunk and proximal extremities). Objective: To determine the efficacy of erythromycin in the treatment of patients with pityriasis rosea. Patients and Methods: In this doubl...
متن کاملThe Nanocurcumin Reduces Appetite in Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): A Double-Blind Randomized Placebo-Controlled Clinical Trial
Objective(s): Various beneficial effects of curcumin have been seen specially as anti-inflammator and antioxidant agent. However, until now no human studies have been done on curcumin’s role in control of appetite. So, the present study was done to determine the effect of nanocurcumin on appetite in obese Non-Alcoholic Fatty Liver Disease (NAFLD) patients.Materials and Methods: This study was d...
متن کاملReduction of some atherogenic indices in patients with non-alcoholic fatty liver by Vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial
The role of non-alcoholic fatty liver disease (NAFLD) as a potential independent cardiovascular disease (CVD) risk factor has recently gained considerable attention because CVD is the common cause of death in NAFLD patients. We aimed to estimate the effects of vitamin D supplementation alone or in combination with calcium on atherogenic indices, liver function tests and grade of disease in pati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Gastroenterology
دوره 137 5 شماره
صفحات -
تاریخ انتشار 2009